Kanaya et al(16) demonstrated that >80% of the CpG sites were methylated in the hMLH1 promoter in ~30% of cases of endometrioid adenocarcinoma, resulting in a reduced expression of the hMLH1 protein. The gene discussed is MLH1; the disease is endometrioid adenocarcinoma.